Patent Granted in USA

AI SummaryClose X

Cizzle Biotechnology Holdings PLC announced that a patent application for its core methods to measure the CIZ1B lung cancer biomarker has been allowed by the U.S. Patent and Trademark Office, strengthening its patent portfolio in the key US market. This patent, concerning a two-step test format licensed to Cizzle Bio Inc for North America and the Caribbean, supports the upcoming launch and commercialization of the company's diagnostic technology. The company also holds patent protection from the European Patent Office and aims to secure further licensing partnerships in the UK and Europe, aligning with the NHS cancer plan to improve early diagnosis rates.

Disclaimer*

UK 100

Latest directors dealings